Most patients received neoadjuvant chemotherapy, modified radical mastectomy, or postmastectomy radiation of the chest wall and draining lymphatics. Neoadjuvant chemotherapy regimens included treatment with doxorubicin (Pharmorubicin RD, Pfizer, New York, USA), and taxane (Docetaxel, Sanofi-Aventis, Paris, France). After every cycle of neoadjuvant chemotherapy, an evaluation of the objective response was made using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 standard.4 (link) The objective response rate (ORR) included both the complete and partial responses. Tamoxifen (Yangzijiang Co, Taizhou, China), or the aromatase inhibitor, Femara (Novartis, Basel, Switzerland) were used in patients with hormone receptor (HR)-positive IBC. The HER-2 targeted therapy using Trastuzumab (Roche, Basel, Switzerland) was recommended for HER-2-positive patients. All of the therapeutic regimens were in compliance with the newest National Comprehensive Cancer network (NCCN) guidelines in the corresponding year.
Pharmorubicin rd
Manufactured by Pfizer
Sourced in United States, China
Pharmorubicin RD is a laboratory equipment product. It is used for research and development purposes.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using pharmorubicin rd
1
Neoadjuvant Chemotherapy and Surgical Management of Inflammatory Breast Cancer
2
Preparation of Carbon Nanoparticle-Epirubicin Suspension
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The carbon nanoparticle-epirubicin suspension was prepared as described previously [16 (link), 17 (link)]. 0.10 mg of epirubicin hydrochloride for injection (Pharmorubicin RD, Pfizer Inc, Wuxi, China) was dissolved in 2 ml of normal saline and mixed thoroughly by moderate shaking. The epirubicin solution was then mixed with 1 ml suspension of carbon nanoparticles (1 ml:50 mg; Chongqing Lummy Pharmaceutical Co., Ltd., Chongqing, China), with shaking and vortexing for 5~10 min to allow complete binding of the nanoparticles and epirubicin. The final nanoparticle-epirubicin suspension was black.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!